SCHEMBL20918157

SCHEMBL20918157

O=C(NC1CC12CCN(c1ccnc3ccccc13)CC2)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 4/20 0.49
▸ ADRB2 P07550 1/20 0.45
▸ NCF1 P14598 1/20 0.45
▸ PDGFRB P09619 1/20 0.45
▸ DRD2 P14416 3/20 0.42
▸ DRD3 P35462 3/20 0.42
▸ AKT1 P31749 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ AR P10275 2/20 0.41
▸ HDAC3 O15379 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HDAC9 Q9UKV0 1/20 0.38
▸ HDAC5 Q9UQL6 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22262734 1.00 SCN9A (0.49) SCN9AADRB2NCF1PDGFRBDRD2
SCHEMBL20918155 1.00 SCN9A (0.49) SCN9AADRB2NCF1PDGFRBDRD2
SCHEMBL22262729 0.85 ADRB2 (0.45) ADRB2NCF1PDGFRBDRD2DRD3
SCHEMBL1709228 0.81 SCN9A (0.69) SCN9ADRD2DRD3KDM4E
SCHEMBL20918521 0.80 IDO1 (0.40) SCN9AARHDAC3ACHEHDAC1
SCHEMBL22262819 0.80 IDO1 (0.40) SCN9AARHDAC3ACHEHDAC1
SCHEMBL20919486 0.80 IDO1 (0.40) SCN9AARHDAC3ACHEHDAC1
SCHEMBL20935310 0.79 IDO1 (0.46) SCN9A
SCHEMBL1709225 0.77 SCN9A (0.66) SCN9ADRD2DRD3
SCHEMBL20918176 0.77 IDO1 (0.56) ADRB2NCF1PDGFRBDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180497-B2 Cyclic compounds as immunomodulating agents ANGEX PHARMACEUTICAL, INC. (US) 2021-11-23 — — US claimed
US-20200239464-A1 CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS ANGEX PHARMACEUTICAL, INC. 2020-07-30 — — US claimed
WO-2019078968-A2 CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS ANGEX PHARMACEUTICAL, INC. (US) 2019-04-25 — — WO claimed
US-11180497-B2 Cyclic compounds as immunomodulating agents ANGEX PHARMACEUTICAL, INC. (US) 2021-11-23 — — US disclosed
US-11180497-B2 Cyclic compounds as immunomodulating agents ANGEX PHARMACEUTICAL, INC. (US) 2021-11-23 — — US disclosed
US-20200239464-A1 CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS ANGEX PHARMACEUTICAL, INC. 2020-07-30 — — US disclosed
US-20200239464-A1 CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS ANGEX PHARMACEUTICAL, INC. 2020-07-30 — — US disclosed
WO-2019078968-A2 CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS ANGEX PHARMACEUTICAL, INC. (US) 2019-04-25 — — WO disclosed
WO-2019078968-A2 CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS ANGEX PHARMACEUTICAL, INC. (US) 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239464-A1 CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS IDO1, IDO2, INMT SCN9A 4530/4885ADRB2 4147/4885NCF1 897/4885
US-11180497-B2 Cyclic compounds as immunomodulating agents IDO1, IDO2, INMT SCN9A 4547/4885ADRB2 4164/4885NCF1 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback